Royalty Pharma (RPRX) Interest Expenses (2019 - 2026)
Royalty Pharma (RPRX) posted Interest Expenses of $223.6 million for Q1 2026, up 487.59% sequentially from $38.1 million in Q4 2025, and up 22.52% YoY from $182.5 million in Q1 2025.
Royalty Pharma (RPRX) Interest Expenses (2019 - 2026) Analysis & Trends
Royalty Pharma has reported Interest Expenses for 8 years, with the latest figure at $223.6 million in Q1 2026.
- Quarterly Interest Expenses rose 22.52% year-over-year to $223.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $223.6 million (up 22.52% YoY) and the FY2025 annual result came in at $307.7 million, up 36.43% from the prior year.
- Interest Expenses improved to $223.6 million in Q1 2026 per RPRX's latest filing, from $38.1 million in the prior quarter.
- Over five years, Interest Expenses peaked at $223.6 million in Q1 2026 and troughed at -$198.9 million in Q1 2022.
- A 5-year average of $72.3 million and a median of $160.6 million in 2024 frame the typical range for Interest Expenses.
- The sharpest annual moves came in 2024 and 2025: Interest Expenses slumped 100.62% in 2024, then soared 21124.31% in 2025.
- Over 5 years, Interest Expenses stood at $663000.0 in 2022, then soared by 4309.65% to $29.2 million in 2023, then slumped by 100.62% to -$181000.0 in 2024, then jumped by 21124.31% to $38.1 million in 2025, then jumped by 487.59% to $223.6 million in 2026.
- According to Business Quant data, Interest Expenses over the past three periods registered $223.6 million, $38.1 million, and $79.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 6.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 218.10 Mn |
| Jun 30, 2026 | 218.10 Mn |
| Mar 31, 2026 | 223.60 Mn |
| Mar 31, 2026 | 223.60 Mn |
| Dec 31, 2025 | 38.05 Mn |
| Dec 31, 2025 | 38.05 Mn |
| Sep 30, 2025 | 79.56 Mn |
| Sep 30, 2025 | 79.56 Mn |
| Jun 30, 2025 | 177.50 Mn |
| Jun 30, 2025 | 177.50 Mn |
| Mar 31, 2025 | 182.50 Mn |
| Mar 31, 2025 | 182.50 Mn |
| Dec 31, 2024 | -181,000.00 |
| Dec 31, 2024 | -181,000.00 |
| Sep 30, 2024 | 192.60 Mn |
| Sep 30, 2024 | 192.60 Mn |
| Jun 30, 2024 | 205.20 Mn |
| Jun 30, 2024 | 205.20 Mn |
| Mar 31, 2024 | 160.60 Mn |
| Mar 31, 2024 | 160.60 Mn |